Please login to the form below

Not currently logged in
Email:
Password:

cancer vaccine

This page shows the latest cancer vaccine news and features for those working in and with pharma, biotech and healthcare.

Moderna posts encouraging early data for personalised cancer vaccine

Moderna posts encouraging early data for personalised cancer vaccine

phase 1 trial evaluating its mRNA-based personalised cancer vaccine. ... We are encouraged by this interim data from our personalised cancer vaccine programme, which involves designing and manufacturing a unique vaccine for each patient based on their

Latest news

  • Keytruda growth helps Merck to offset COVID-19 impact in Q3 Keytruda growth helps Merck to offset COVID-19 impact in Q3

    The growth in profits was mainly due to increasing demand for certain drugs, including its blockbuster checkpoint inhibitor Keytruda (pembrolizumab), and its bacterial pneumonia vaccine. ... Merck is currently developing an oral antiviral candidate for

  • Newly-listed BioNTech buys Neon to boost cell therapy assets Newly-listed BioNTech buys Neon to boost cell therapy assets

    BioNTech has agreed to pay $67m for Cambridge, Massachusetts-based Neon, which ended 2019 on a sour note by dropping its clinical-stage personalised cancer vaccine NEO-PV-01 after disappointing ... Also in the pipeline is NEO-STC-01, another RAS-targeted

  • Merck strengthens KRAS stake with Taiho and Astex partnership Merck strengthens KRAS stake with Taiho and Astex partnership

    At MSD we continue to pursue new regimens designed to extend the benefits of highly selective therapies to more patients with cancer,” said Roger Perlmutter (pictured left), president, MSD Research Laboratories. ... Merck also has an ongoing

  • Merck CFO: we’re not only about Keytruda Merck CFO: we’re not only about Keytruda

    He said the performance of other cancer drugs like Lenvima (lenvatinib) and Lynparza (olaparib), revenue from which doubled in the quarter – as well as the vaccine portfolio headed by cervical cancer ... vaccine Gardasil and HIV franchise – is

  • GSK eyes follow-up HPV vaccine GSK eyes follow-up HPV vaccine

    Cervarix from the US market after finding it was not competitive against rival Merck &Co’s HPV vaccine. ... Innovax has already developed a cervical cancer vaccine, Cecolin, which is HPV 16 &18 bivalent – these two HPV types are known to cause at

More from news
Approximately 2 fully matching, plus 149 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?

  • Pharma deals in August 2015 Pharma deals in August 2015

    This was the fifth deal announced by AstraZeneca/Medimmune in the month under which the company gained access to INO-3112 a cancer vaccine which targets cancers caused by human papilloma ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112

  • Pharma deals in March 2015 Pharma deals in March 2015

    The companies will collaborate to develop three anti-cancer drugs, one Mab from Lilly and a Mab and an additional molecule from Innovent. ... This is what BMS has secured with Bavarian Nordic's cancer vaccine targeting PSA in phase III for treatment of

  • Pharma deals in February 2015 Pharma deals in February 2015

    This month saw the deadline, highlighted in January's Deal Watch, for Valeant to acquire Dendreon, and more specifically the dendritic cell, prostate cancer vaccine Provenge (sipuleucel-T), come and go.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    R&D and. commercialisation. IMA942 tumour-associated peptide cancer vaccine candidates in NSCLC and prostate cancer. ... BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Secondary effects of COVID-19 on the healthcare system and patients

    To date, most of the focus has understandably been on the immediate effects of the virus and the efforts to enforce physical distancing and develop a vaccine.

  • Understanding the "Big Picture"

    A good example of this is Globocan cancer epidemiology data, which is extremely high level but does not provide insight as to staging or treatment rates. ... A good example of this “Risk-awareness thinking” would be the impact of the cervical cancer

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics